BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...Inc. (NASDAQ:SUPN) hired James Kelly as CFO, effective Oct. 12. Kelly, who was CFO of Vanda Pharmaceuticals Inc....
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

...immunized, transgenic cows. CSL will contribute clinical, regulatory, manufacturing and supply chain expertise and resources. Vanda Pharmaceuticals Inc....
...and Elizabeth S. Eaton, Staff Writer I-Mab Biopharma U.S. Department of Health and Human Services SAB Biotherapeutics Inc. CSL Ltd. Vanda Pharmaceuticals Inc. University...
BioCentury | Feb 26, 2020
Product Development

Subgroup analyses help Vanda hold steady despite Phase III itch miss

...in the Phase III EPIONE trial to treat atopic dermatitis in patients with severe pruritus. Vanda Pharmaceuticals Inc....
...itch by >4 points in more patients than placebo (72.5% vs. 33.3%, p=0.0007). According to Vanda...
...in April. Targets NK1R (TACR1) - Neurokinin 1 receptor Sandi Wong, Assistant Editor serlopitant (VPD-737, mk-0594) tradipitant (ly686017, vly-686) Vanda Pharmaceuticals Inc. Menlo...
BioCentury | Feb 26, 2020
Product Development

Feb. 25 Quick Takes: Vanda’s Phase III miss; plus Iovance; 1st-twoXAR; app for AFib, stroke; ICER-Aetion; new-look Purple Book, and more

...Vanda’s itch therapy misses in atopic dermatitis Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares tumbled after market close Tuesday after...
...score -- tradipitant reduced WI-NRS scores by 4.36 points vs. 3.28 points for placebo (p=0.0217). Vanda...
...factor Sandi Wong, Assistant Editor, and Paul Bonanos, Associate Editor tradipitant (ly686017, vly-686) Eylea, VEGF Trap-Eye, aflibercept ophthalmic solution Vanda Pharmaceuticals Inc. 1st...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...CSO, effective March 2. He co-founded and was SVP of research at eFFECTOR Therapeutics Inc. Vanda Pharmaceuticals Inc....
BioCentury | Jan 13, 2020
Politics & Policy

Supreme Court declines to clean up its IP mess

...not to review Athena’s case, along with two other cases, Hikma Pharmaceuticals, et al. v. Vanda...
BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

...for Vanda's jet lag treatment FDA declined to approve an NDA for Hetlioz tasimelteon from Vanda Pharmaceuticals Inc....
...Mary Romeo, Assistant Editor cefiderocol (S-649266) Hetlioz, tasimelteon (VEC-162) MRNA-1893 Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Moderna Inc. PharmaMar S.A. Shionogi & Co. Ltd. Vanda Pharmaceuticals Inc....
BioCentury | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

...treat Parkinson's disease psychosis to $320-$330 million from $280-$300 million. Vanda gains after Citi upgrade Vanda Pharmaceuticals Inc....
...the company to buy, citing the “immediate and significant upside” for motion sickness candidate tradipitant. Vanda...
...Informal), clonoSEQ Assay (Informal) Acadia Pharmaceuticals Inc. Adaptive Biotechnologies Eton Pharmaceuticals Inc. Evotec SE Innovative Medicines Initiative (IMI) Nektar Therapeutics University of Bristol Vanda Pharmaceuticals Inc. Lygature...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...Pre $2.49 $3.98 -37% Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) 7/31 Post NA ¥100.05 NA Vanda Pharmaceuticals Inc....
BioCentury | May 10, 2019
Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

...in April after the stakeholder group's fourth meeting. Sidebar: Conflicting court rulings continue The 2018 Vanda Pharmaceuticals Inc....
...While the Mayo patent's first claim was worded as "a method for optimizing therapeutic efficacy," Vanda...
...for treating." Patent attorneys interviewed by BioCentury in January were optimistic about the potential workaround Vanda...
Items per page:
1 - 10 of 259
BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...Inc. (NASDAQ:SUPN) hired James Kelly as CFO, effective Oct. 12. Kelly, who was CFO of Vanda Pharmaceuticals Inc....
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

...immunized, transgenic cows. CSL will contribute clinical, regulatory, manufacturing and supply chain expertise and resources. Vanda Pharmaceuticals Inc....
...and Elizabeth S. Eaton, Staff Writer I-Mab Biopharma U.S. Department of Health and Human Services SAB Biotherapeutics Inc. CSL Ltd. Vanda Pharmaceuticals Inc. University...
BioCentury | Feb 26, 2020
Product Development

Subgroup analyses help Vanda hold steady despite Phase III itch miss

...in the Phase III EPIONE trial to treat atopic dermatitis in patients with severe pruritus. Vanda Pharmaceuticals Inc....
...itch by >4 points in more patients than placebo (72.5% vs. 33.3%, p=0.0007). According to Vanda...
...in April. Targets NK1R (TACR1) - Neurokinin 1 receptor Sandi Wong, Assistant Editor serlopitant (VPD-737, mk-0594) tradipitant (ly686017, vly-686) Vanda Pharmaceuticals Inc. Menlo...
BioCentury | Feb 26, 2020
Product Development

Feb. 25 Quick Takes: Vanda’s Phase III miss; plus Iovance; 1st-twoXAR; app for AFib, stroke; ICER-Aetion; new-look Purple Book, and more

...Vanda’s itch therapy misses in atopic dermatitis Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares tumbled after market close Tuesday after...
...score -- tradipitant reduced WI-NRS scores by 4.36 points vs. 3.28 points for placebo (p=0.0217). Vanda...
...factor Sandi Wong, Assistant Editor, and Paul Bonanos, Associate Editor tradipitant (ly686017, vly-686) Eylea, VEGF Trap-Eye, aflibercept ophthalmic solution Vanda Pharmaceuticals Inc. 1st...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...CSO, effective March 2. He co-founded and was SVP of research at eFFECTOR Therapeutics Inc. Vanda Pharmaceuticals Inc....
BioCentury | Jan 13, 2020
Politics & Policy

Supreme Court declines to clean up its IP mess

...not to review Athena’s case, along with two other cases, Hikma Pharmaceuticals, et al. v. Vanda...
BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

...for Vanda's jet lag treatment FDA declined to approve an NDA for Hetlioz tasimelteon from Vanda Pharmaceuticals Inc....
...Mary Romeo, Assistant Editor cefiderocol (S-649266) Hetlioz, tasimelteon (VEC-162) MRNA-1893 Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Moderna Inc. PharmaMar S.A. Shionogi & Co. Ltd. Vanda Pharmaceuticals Inc....
BioCentury | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

...treat Parkinson's disease psychosis to $320-$330 million from $280-$300 million. Vanda gains after Citi upgrade Vanda Pharmaceuticals Inc....
...the company to buy, citing the “immediate and significant upside” for motion sickness candidate tradipitant. Vanda...
...Informal), clonoSEQ Assay (Informal) Acadia Pharmaceuticals Inc. Adaptive Biotechnologies Eton Pharmaceuticals Inc. Evotec SE Innovative Medicines Initiative (IMI) Nektar Therapeutics University of Bristol Vanda Pharmaceuticals Inc. Lygature...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...Pre $2.49 $3.98 -37% Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) 7/31 Post NA ¥100.05 NA Vanda Pharmaceuticals Inc....
BioCentury | May 10, 2019
Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

...in April after the stakeholder group's fourth meeting. Sidebar: Conflicting court rulings continue The 2018 Vanda Pharmaceuticals Inc....
...While the Mayo patent's first claim was worded as "a method for optimizing therapeutic efficacy," Vanda...
...for treating." Patent attorneys interviewed by BioCentury in January were optimistic about the potential workaround Vanda...
Items per page:
1 - 10 of 259